The Role of Biomarkers in Detection of Cardio-toxicity.

Related Articles

The Role of Biomarkers in Detection of Cardio-toxicity.

Curr Oncol Rep. 2017 Jun;19(6):42

Authors: Shah KS, Yang EH, Maisel AS, Fonarow GC

Abstract
The goal of this paper is to review the current literature on the role of biomarkers in the detection and management of patients with cardio-oncologic disease. The role of biomarker surveillance in patients with known cardiac disease, as a result of chemotherapy or with the potential to develop cardio-toxicity, will be discussed. In addition, the studies surrounding sub-clinical cardiac toxicity monitoring during therapy, identification of high-risk patients prior to therapy, and tailoring oncologic therapies to potential biomarker risk profiles are reviewed. Based on evidence, to date, troponin and natriuretic peptides have the greatest potential to detect sub-clinical cardiac dysfunction and even tailor therapy to prevent progression based on biomarker profiles. Finally, future directions for potential utilization of novel biomarkers for the improvement of care of patients in the field of cardio-oncology are discussed.

PMID: 28421484 [PubMed - in process]

http://ift.tt/2oO1wJd